JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott maintains an Overweight rating on Gilead Sciences and raises the price target from $95 to $100.
October 09, 2024 | 8:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has reaffirmed its Overweight rating on Gilead Sciences and increased the price target from $95 to $100, indicating a positive outlook.
The increase in price target from $95 to $100 by JP Morgan suggests a positive outlook for Gilead Sciences, likely boosting investor confidence and potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100